Analyzing the overlap between candidate drug against EVD based on the Kouznetsova et al. study and those generated by CANDO (Table 2), we observe the following: Five drugs act upon the cardiac myocyte cell membrane (two sodium channel blockers, two sodium-potassium channel blockers, and one potassium channel blocker) and are used to treat various cardiac arrhythmias. The gene discussed is KCNA3; the disease is cardiac arrhythmia.